In a groundbreaking advancement in oral cancer prevention, researchers at The University of Texas MD Anderson Cancer Center have unveiled a promising new approach involving the direct injection of nivolumab, an immune checkpoint inhibitor, into precancerous oral lesions. This novel technique, presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, has demonstrated substantial efficacy in reducing lesion size and mitigating the risk of progression to oral cancer, all while significantly sparing patients from the need for invasive surgical interventions.
Oral cancer remains a formidable health challenge, often preceded by dysplastic lesions within the oral cavity. Traditionally, clinicians have relied on the surgical removal or ablation of these lesions to prevent malignant transformation, a practice that can lead to considerable morbidity due to the loss of oral tissue. Given the multifocal nature of these lesions and their propensity to recur, patients frequently undergo repeated surgeries, resulting in complications like impaired speech, swallowing difficulties, and diminished quality of life.
The standard systemic administration of nivolumab, an anti-PD-1 monoclonal antibody, has shown efficacy in managing various cancers, including oral malignancies. However, its high dosage when given intravenously can provoke severe systemic toxicities, which are especially concerning for patients who have yet to develop cancer but suffer from precancerous lesions. To address this clinical dilemma, Dr. Moran Amit and colleagues embarked on a first-in-human Phase I trial that explored a radically different delivery method: low-dose, local intralesional injections of nivolumab directly into the lesions.
This investigative trial involved 29 patients with varying severities of oral dysplasia, from mild to severe, who received weekly intralesional injections of 10 or 20 mg of nivolumab for four cycles. By administering a dose that represents merely 2-4% of the conventional systemic amount, the researchers hypothesized that the bioavailability of the drug at the targeted site would be maximized while systemic exposure—and thus, toxicity—would be minimized. This approach leverages the principle that localized drug delivery can potentiate immune activation specifically within the lesion microenvironment.
The clinical outcomes were striking. After a median follow-up time of 14.5 months, 85% of patients exhibited a measurable decrease in lesion size, averaging a 60% reduction. Notably, over half of these patients experienced shrinkage beyond 50%. Moreover, pathological reassessment revealed that 41% of lesions were downgraded in severity, with six individuals achieving complete pathological remission, indicating a complete absence of dysplasia. Importantly, only six lesions progressed to invasive cancer, but these were promptly managed surgically with no further progression in the cohort.
Safety profiles further underscored the promise of this therapeutic strategy. The majority of adverse events were mild to moderate, including isolated cases of diarrhea, hyperglycemia, and acidosis. Critically, no dose-limiting toxicities emerged, and the overall tolerability of the treatment was exceptional, offering a substantial advantage over systemic nivolumab regimens known for their pronounced immune-related side effects.
Immunological analyses provided mechanistic insights into how this localized immunotherapy modulated the tumor microenvironment. Treated lesions demonstrated increased infiltration of CD4 and CD8 T cells along with other markers signifying immune activation. This local immune engagement suggests that intralesional nivolumab reprograms the lesion milieu, fostering an environment hostile to malignant transformation. Pharmacokinetic measurements corroborated the localized nature of treatment, revealing nivolumab blood concentrations below 10 micrograms per milliliter—significantly lower than systemic administration levels.
The implications of this study extend far beyond oral cancer precursors. Precancerous lesions are common in diverse epithelial cancers such as those of the skin, cervix, and colon, raising the possibility that similar localized immunotherapeutic interventions could revolutionize preventive oncology. By circumventing the systemic toxicities associated with immune checkpoint inhibitors, this approach opens a new frontier in cancer prevention through immune interception, aligning with the broader goal of precision medicine.
Looking forward, the research team is preparing to launch a Phase II placebo-controlled clinical trial designed to target multiple lesions simultaneously, thereby addressing a critical limitation of the initial study which treated only a single lesion at a time. Success in this upcoming trial could establish intralesional nivolumab as a standard-of-care alternative or complement to surgery, tremendously improving patient quality of life by maintaining oral functionality and avoiding the disfiguring consequences of repeated resections.
Dr. Amit emphasizes that transforming these once ominous lesions from “bad actors” into manageable clinical findings that can be closely monitored without surgery represents a seismic shift in oral cancer prevention. The approach harnesses immune mechanisms precisely where they are needed, offering a potent but gentle means to halt disease progression before cancer emerges.
This pioneering research was supported by the Cancer Prevention and Research Institute of Texas and embodies a synergy of innovative scientific thought and clinical pragmatism. As immunotherapy continues to reshape oncology, the findings highlight the untapped potential of localized treatments that reconcile efficacy with patient-centric tolerability. Such advances promise not only to extend lives but also to preserve the quality of those lives, embodying the true essence of transformative medical progress.
For patients at risk of oral cancer, this therapy could well be a beacon of hope, marking a future where cancer prevention and symptom management transcend the limitations of invasive surgical approaches and systemic cytotoxicity. As ongoing investigations delve deeper into immune checkpoint inhibitors’ localized applications, the oncology community eagerly anticipates a paradigm shift that redefines how precancerous conditions are viewed and treated.
Subject of Research: Immune checkpoint inhibitor therapy for precancerous oral lesions
Article Title: Localized Nivolumab Injection Dramatically Reduces Precancerous Oral Lesion Burden and Cancer Risk
News Publication Date: April 21, 2026
Web References:
– https://www.mdanderson.org/research/research-resources/conferences-seminars/md-anderson-at-aacr.html
– https://faculty.mdanderson.org/profiles/moran_amit.html
– https://www.abstractsonline.com/pp8/#!/21436/presentation/12094
References: Clinical data from the Phase I trial presented at AACR 2026
Image Credits: The University of Texas MD Anderson Cancer Center
Keywords: Oral cancer, immunotherapy, immune checkpoint inhibitor, nivolumab, precancerous lesions, oral dysplasia, intralesional injection, cancer prevention, immune activation, Phase I clinical trial, head and neck cancer, immune response
Tags: AACR 2026 oral cancer researchavoiding surgery in oral precancerous conditionsimmune checkpoint inhibitors in oral cancerinnovative cancer immunotherapy methodslocal immunotherapy for oral cancernivolumab injection for precancerous oral lesionsnon-surgical treatment for oral dysplastic lesionsoral cancer prevention strategiesoral lesion size reduction techniquesPD-1 inhibitors in cancer therapyquality of life improvements in oral cancer patientsreducing oral lesion progression risk
